Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -6.9x - -7.7x | -7.3x |
| Selected Fwd P/E Multiple | -54.0x - -59.7x | -56.8x |
| Fair Value | €2.94 - €3.25 | €3.10 |
| Upside | -15.3% - -6.4% | -10.8% |
| Benchmarks | - | Full Ticker |
| Amphastar Pharmaceuticals, Inc. | - | NasdaqGS:AMPH |
| Corcept Therapeutics Incorporated | - | NasdaqCM:CORT |
| Teva Pharmaceutical Industries Limited | - | OTCPK:TEVJ.F |
| Recordati Industria Chimica e Farmaceutica S.p.A. | - | OTCPK:RCDT.F |
| Novo Nordisk A/S | - | OTCPK:NONO.F |
| Xeris Biopharma Holdings, Inc. | - | DB:2B30 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| AMPH | CORT | TEVJ.F | RCDT.F | NONO.F | 2B30 | |||
| NasdaqGS:AMPH | NasdaqCM:CORT | OTCPK:TEVJ.F | OTCPK:RCDT.F | OTCPK:NONO.F | DB:2B30 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 26.7% | 8.2% | NM- | 2.5% | 21.0% | NM- | ||
| 3Y CAGR | 36.9% | 7.5% | NM- | 2.6% | 28.4% | NM- | ||
| Latest Twelve Months | 16.0% | 32.5% | -193.2% | 7.0% | 20.7% | 11.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 14.5% | 26.6% | -10.5% | 21.3% | 33.7% | -407.3% | ||
| Prior Fiscal Year | 21.3% | 21.9% | -3.5% | 18.7% | 36.0% | -38.0% | ||
| Latest Fiscal Year | 21.8% | 20.7% | -9.9% | 17.8% | 34.8% | -27.0% | ||
| Latest Twelve Months | 21.8% | 20.7% | -9.9% | 17.8% | 34.8% | -27.0% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 6.1x | 48.2x | 6.9x | 13.8x | 13.2x | -54.3x | ||
| Price / LTM Sales | 1.6x | 10.7x | 0.9x | 4.1x | 6.4x | 3.2x | ||
| LTM P/E Ratio | 7.2x | 51.8x | -9.4x | 23.1x | 18.5x | -11.7x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -9.4x | 18.5x | 51.8x | |||||
| Historical LTM P/E Ratio | -11.7x | -3.9x | -1.4x | |||||
| Selected P/E Multiple | -6.9x | -7.3x | -7.7x | |||||
| (x) LTM Net Income | (55) | (55) | (55) | |||||
| (=) Equity Value | 380 | 400 | 420 | |||||
| (/) Shares Outstanding | 153.9 | 153.9 | 153.9 | |||||
| Implied Value Range | 2.47 | 2.60 | 2.73 | |||||
| FX Rate: USD/EUR | 1.1 | 1.1 | 1.1 | Market Price | ||||
| Implied Value Range (Trading Cur) | 2.18 | 2.29 | 2.41 | 3.48 | ||||
| Upside / (Downside) | -37.3% | -34.0% | -30.7% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | AMPH | CORT | TEVJ.F | RCDT.F | NONO.F | 2B30 | |
| Value of Common Equity | 1,151 | 7,240 | 15,731 | 8,914 | 1,883,416 | 607 | |
| (/) Shares Outstanding | 47.7 | 105.5 | 1,145.8 | 206.3 | 4,439.1 | 153.9 | |
| Implied Stock Price | 24.16 | 68.62 | 13.73 | 43.21 | 424.28 | 3.94 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 0.88 | 6.58 | 1.13 | |
| Implied Stock Price (Trading Cur) | 24.16 | 68.62 | 13.73 | 49.00 | 64.44 | 3.48 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 0.88 | 6.58 | 1.13 | |